Tanya Simuni

Tanya Simuni

Auto-generated profile, based on publicly available information

Tanya Simuni

Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2024 in The Lancet Neurology
Verified
Journal Article
Closed access
TSTanya Simuni
Tanya Simuni
LCLana M Chahine
Lana M Chahine
KPKathleen Poston
Kathleen Poston
MBMichael Brumm
Michael Brumm
TBTeresa Buracchio
Teresa Buracchio
KMKenneth Marek
Kenneth Marek

1 April 2014 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
AVAleksandar Videnovic
Aleksandar Videnovic
CNCharleston Noble
Charleston Noble
KRKathryn Reid
Kathryn Reid
JPJie Peng
Jie Peng
FTFred Turek
Fred Turek
PZPhyllis C. Zee
Phyllis C. Zee
Disturbances of sleep and wake are among the most common and disabling nonmotor manifestations of Parkinson disease (PD), affecting as many as 90% of patients.1,2 Disrupted sleep-wake cycles contribute to poor quality of life and increased risk for accidents, leading to increased morbidity and mortality in the PD population.3-5 Current treatment options for disturbed sleep and alertness in PD are very limited and are associated with undesirable adverse effects. Therefore, the need to understand the mechanisms leading to sleep-wake dysfunction in PD and to develop innovative treatment modalities is great. The exact pathophysiological features of sleep-wake disturbances in PD remain largely unknown, but the cause is likely to be multifactorial, including the effect of motor symptoms on sleep, primary sleep disorders (sleep apnea and Rapid Eye Movement Sleep Behavior Disorder), adverse effects of medications, and neurodegeneration of central sleep-wake regulatory systems.6-9

23 March 2018 in Movement Disorders
Verified
Journal Article
Open access
PDF file
TSTanya Simuni
Tanya Simuni
ASAndrew Siderowf
Andrew Siderowf
SLShirley Lasch
Shirley Lasch
CCChris S. Coffey
Chris S. Coffey
CCChelsea Caspell‐Garcia
Chelsea Caspell‐Garcia
TIThe Parkinson'S Progression Marker Initiative
The Parkinson'S Progression Marker Initiative
Objective: The objective of this study was to assess longitudinal change in clinical and dopamine transporter imaging outcomes in early, untreated PD.Methods: We describe 5‐year longitudinal change of the MDS‐UPDRS and other clinical measures using results from the Parkinson's Progression Markers Initiative, a longitudinal cohort study of early Parkinson's disease (PD) participants untreated at baseline. We also provide data on the longitudinal change in dopamine transporter 123‐I Ioflupane striatal binding and correlation between the 2 measures.Results: A total of 423 PD participants were recruited, and 358 remain in the study at year 5. Baseline MDS‐UPDRS total score was 32.4 (standard deviation 13.1), and the average annual change (assessed medications OFF for the treated participants) was 7.45 (11.6), 3.11 (11.7), 4(11.9), 4.7 (11.1), and 1.74(11.9) for years 1, 2, 3, 4, and 5, respectively (P < .0001 for the change over time), with a steeper change in year 1. Dopaminergic therapy had a significant effect on the change of MDS‐UPDRS. There was a significant longitudinal change in dopamine transporter binding in all striatal regions (P < .001). There was a significant but weak correlation between MDS‐UPDRS and dopamine transporter binding at baseline and years 1, 2, and 4, but no correlation between the rate of change of the 2 variables.Conclusions: We present 5‐year longitudinal data on the change of the MDS‐UPDRS and other clinical and dopamine transporter imaging outcome measures in early PD. These data can be used for sample size estimates for interventional studies in the de novo PD population. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

1 July 2016 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
TSTanya Simuni
Tanya Simuni
CCChelsea Caspell-Garcia
Chelsea Caspell-Garcia
CCChristopher Coffey
Christopher Coffey
SLShirley Lasch
Shirley Lasch
CTCaroline Tanner
Caroline Tanner
KMKen Marek
Ken Marek

6 January 2009 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
TSTanya Simuni
Tanya Simuni
KSKapil Sethi
Kapil Sethi

1 March 2021 in JAMA Neurology
Verified
Journal Article
Closed access
PDF file
TSTanya Simuni
Tanya Simuni
BFBrian Fiske
Brian Fiske
KMKalpana Merchant
Kalpana Merchant
CCChristopher S. Coffey
Christopher S. Coffey
EKElizabeth Klingner
Elizabeth Klingner
COCollaborators
Collaborators
Parkinson disease (PD) is the second most common neurodegenerative disease, affecting 1% of the population older than 65 years.1 Slowing PD progression remains a major unmet need.2 Nilotinib, an approved therapy for chronic myeloid leukemia, works predominantly via BCR-Abelson tyrosine kinase (c-Abl) inhibition. It is neuroprotective in animal models of PD,3-5 leading to an interest in its development to slow PD progression. However, nilotinib has safety and tolerability liability.6 At the time of the study launch, the clinical experience with nilotinib in PD was limited to a small study,7 warranting further careful investigation. Since then, results of a phase 2 study,8 undertaken by the same group, were reported in 2020 where nilotinib showed acceptable safety and tolerability in moderately advanced PD and favorable changes in exploratory biomarkers of PD pathophysiology without significant effects on clinical outcomes. The primary objective of this multicenter study was to assess safety and tolerability of nilotinib in participants, with moderately advanced PD with secondary and exploratory outcomes, respectively, of effect on PD disability, pharmacokinetics, and biomarkers’ assessment.